19-norhydroxyprogesterone caproate(SH-582)による前立腺肥大症の治療について

Abstract

1) SH-582 was used in 25 cases of prostatic hypertrophy over an average period of 5 months. Clinical symptoms were improved in 60 to 70 % of those cases. 2) Animal experiments in rats demonstrated an atrophy of the ventral lobe of the prostate. 3) It was presumed that the effects of SH•582 in reducing the prostate might be ascribable to its inhibitory action not on the central but on the peripheral system, or, to be more accurate, on the prostate itself. 4) There were no severe side-effects following administration of SH-582. However, great care should be taken when patients having complications of diabetes or hepatic disturbances are treated with SH-582.